Vibalogics is a privately-owned contract development and manufacturing organization (CDMO) offering process development, manufacturing, testing, and fill-finish services to innovators developing revolutionary virotherapy products.
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
The facility will be equipped with state-of the-art technology and enable a significant capacity increase, including 2000L scale bioreactors and additional fill-finish capabilities.
Vibalogics’ Chief Executive Officer Tom Hochuli is leading the CDMO’s U.S. expansion and global growth strategy. He said: “We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand.
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.SCROLL DOWN
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
The facility will be equipped with state-of the-art technology and enable a significant capacity increase, including 2000L scale bioreactors and additional fill-finish capabilities.
Vibalogics’ Chief Executive Officer Tom Hochuli is leading the CDMO’s U.S. expansion and global growth strategy. He said: “We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand.
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes inruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021. the production of oncolytic vi
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
The CDMO which specializes inruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021. the production of oncolytic vi
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.
With the race for COVID-19 vaccines heating up and the cell and gene therapy market booming, contract manufacturers in the viral vector space are quickly bulking up to meet demand. Hoping to ride that wave, Germany's Vibalogics is planting its flag in the U.S. with a new leader in place.
Months after appointing a new global CEO, German contract manufacturer Vibalogics will shell out $150 million to build out a 110,000-square-foot "virotherapy" facility near Boston set to come online in the second half of 2021, the company said Wednesday.
The new facility will be built out over three years and eventually house 2,000 liters of bioreactor capacity, dedicated to producing clinical and commercial-stage oncolytic viruses and viral vectors used in vaccines and cell and gene therapies, Vibalogics said in a release. The work may include manufacturing for Johnson & Johnson's COVID-19 vaccine candidate under a deal the partners inked in May.
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m